Abstract: Despite a well-characterized lack of specificity, pathologists routinely employ S100 in the diagnosis of neural crest-derived tumors. Recent studies have shown that Sox10 is a reliable marker of neural crest differentiation that is consistently expressed in schwannian and melanocytic tumors. We sought to validate these results in a larger series of soft tissue neoplasms of both neural crest and non-neural crest origin, and to further characterize the sensitivity and specificity of Sox10 for use in clinical diagnosis. We evaluated Sox10 and S100 mRNA levels in 122 cases of peripheral nerve sheath tumors and synovial sarcoma and used immunohistochemistry for Sox10 and S100 protein expression in 1012 tissue specimens. This study includes 174 tissue microarray cases previously reported by Nonaka and colleagues, which include cases of melanoma, dermatofibrosarcoma protuberans, neurofibroma, synovial sarcoma, clearcell sarcoma, malignant peripheral nerve sheath tumor (MPNST), perineurioma, and schwannoma. Synovial sarcomas expressed significantly higher levels of S100B than Sox10 (P = 7.9 Â10 À 9 ), and no significant Sox10 mRNA expression was identified in synovial sarcoma (n = 40), whereas 18/40 cases showed comparatively increased levels of S100 mRNA. The majority of schwannomas (n = 26) and neurofibromas (n = 28) showed relatively an increased expression of both Sox10 and S100 mRNA. MPNSTs (n = 28) showed variable levels of Sox10 and S100 mRNA expression, and these expression levels were highly correlated (Pearson correlation coefficient r = 0.79). In contrast, immunohistochemistry performed on a larger and more varied number of cases highlighted significant differences between the 2 proteins. We identified 5 non-neural, nonmelanocytic sarcoma types in which a subset of cases showed S100 protein expression: synovial sarcoma (12/79, 15%), Ewing sarcoma (3/14, 21%), rhabdomyosarcoma (4/17, 24%), chondrosarcoma (3/4, 75%), and extraskeletal myxoid chondrosarcoma (5/11, 45%). For each of these entities, we identified cases with strong and diffuse S100 staining. Of these cases, only 1 case of rhabdomyosarcoma showed focal Sox10 positivity. In 78 cases of MPNST, S100 increased the sensitivity (31/78, 40%) as compared with Sox10 (21/78, 27%), but the majority of these cases were negative for both Sox10 and S100 (44/78, 56%). Sox10 proved superior to S100 in the detection of desmoplastic melanoma (7/9, 78%) and clear-cell sarcoma (4/7, 57%). We also report for the first time Sox10 expression in 26 cases of granular cell tumor, further supporting the neural crest derivation of this tumor. Excluding MPNST, S100 and Sox10 showed similar sensitivity in tumors of neural crest origin (140/148, 95% and 137/148, 93%, respectively). In summary, Sox10 shows an increased specificity for tumors of neural crest origin compared with S100: Sox10 was positive in only 5 of 668 cases (99% specificity) in nonschwannian, nonmelanocytic tumors, whereas S100 was positive in 53 of 668 cases (91% specificity). Sox10 should be used in the place of or along with S100 in soft tissue tumor diagnosis.
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Key Words: Sox10, S100 protein, neural crest, Schwann cell, schwannoma, synovial sarcoma, MPNST, peripheral nerve sheath tumors N akajima et al 1 first described the results of S100 protein staining in formalin-fixed paraffin-embedded material for a large number of tumors and tissues in 1982 and concluded that S100 was a useful diagnostic tool in tumor diagnosis. This work also showed that S100 was also variably expressed in tissues of adipocytic, chondroid, and myoepithelial derivation, as well as staining interdigitating dendritic cells and Langerhans cells. 1 Later studies showed that S100 was expressed in many nonneural crest-derived tumors including Ewing sarcoma, rhabdomyosarcoma, and synovial sarcoma. [2] [3] [4] [5] Despite its limited specificity, S100 is commonly used as the major tool to determine neural crest differentiation and is frequently deployed by pathologists when faced with a spindle cell neoplasm of uncertain differentiation. S100 is a family of proteins containing 2 EF-hand calciumbinding motifs. S100B is more abundantly expressed in glial cells, melanocytes, adipocytes, and chondrocytes. S100 protein antibodies are often polyclonal but are typically strongly reactive against S100B.
Sox10, a member of the sex-determining region Y-related HMG-box family, is a recently characterized marker of neural crest differentiation that has also been implicated as a neural crest stem cell marker. 6, 7 Several human pathologies are associated with Sox10 mutations including Hirschprungs disease and Waardenburg syndrome. [8] [9] [10] Intact Sox10 signaling is required for normal central and peripheral nervous system myelination. [11] [12] [13] Previous studies have demonstrated that Sox10 is a more sensitive and specific marker than S100 for schwannian and melanocytic tumors.
14 In this study we sought to confirm the findings reported by Nonaka and colleagues in a larger set of neural crest tumors as well as in a wide array of benign and malignant soft tissue neoplasms of known and unknown histogenesis to determine the sensitivity and specificity of Sox10 as compared with S100 for clinical diagnostic use. We also compared Sox10 and S100 mRNA expression in schwannomas, neurofibromas, malignant peripheral nerve sheath tumors (MPNSTs), and synovial sarcomas.
MATERIALS AND METHODS

Gene Expression Profiling
The data set consisted of 122 cases (40 synovial sarcomas, 26 schwannomas, 26 neurofibromas, and 28 MPNSTs). Prior analyses on these cases have been published 15 and the data set is publicly available in the Stanford Microarray Database (http://smd.stanford.edu). 16 
Tissue Microarray Construction
Tissue microarrays (TMAs) were assembled according to established protocols. The following tissue microarrays were used in this study: TA19, TA138, TA166, TA171. These microarrays have been described in published studies. 17, 18 TA138 was also previously evaluated for Sox10 and S100B reactivity in the 2008 study by Nonaka et al. 14 
Immunohistochemistry
Four-micrometer TMA sections and conventional sections were stained for both Sox10 and S100. Reagents and conditions including clone, vendor, and dilution are summarized in Table 1 . Standard 4-mm paraffin block tissue sections from 14 synovial sarcomas, 6 cellular schwannomas, 1 Ewing sarcoma/primitive neuroectodermal tumor and 1 rhabdomyosarcoma were also examined for both Sox10 and S100 expression. The polyclonal S100 antibody used shows strong labeling of S100B, weak labeling of S100A1, and very weak labeling of S100A6.
Nuclear staining in tumor cells was required for a positive interpretation for both S100 and Sox10 stains. The pattern of immunostaining was scored on a 3-tiered scale (0 to 2), with a score of 0 indicating no staining, a score of 1 indicating focal nuclear staining, and a score of 2 indicating staining in the majority of lesional cells. For those cases where multiple TMA scores were evaluated from the same specimen and where scores differed, the highest score was assigned. For the purpose of calculating sensitivity and specificity, a score >0 was counted as positive.
RESULTS
Gene Expression Analysis
The relative Sox10 and S100B gene expression levels were assessed in 122 publically available cases of MPNST, scwhannoma, neurofibroma, and synovial sarcoma. The raw expression data were mean centered by individual array. None of the 40 cases of synovial sarcoma showed relatively an increased expression of SOX10, though 18/ 40 cases had relatively an increased S100B mRNA expression (Fig. 1) . A paired Student t test confirmed that synovial sarcomas express significantly lower levels of SOX10 than S100B (P = 7.9 Â 10 À 9 ). The majority of both schwannomas and neurofibromas showed relatively an increased expression of SOX10 and S100. Sox10 and S100 expression was highly correlated in schwannomas (Pearson correlation coefficient r = 0.89), and neurofibromas (r = 0.79). MPNSTs had variable but significantly correlated levels of S100 and SOX10 expression (r = 0.79).
Immunohistochemical Studies
We examined Sox10 and S100 protein expression of these markers in 1012 specimens representing 66 diagnostic entities and 33 normal tissues. These studies included 174 cases previously studied by Nonaka and colleagues, which included 9 cases of melanoma, 15 cases of dermatofibrosarcoma protuberans, 43 cases of neurofibroma, 15 cases of synovial sarcoma, 5 cases of clear-cell sarcoma, 61 cases of MPNST, 4 cases of perineurioma, Strong and diffuse S100 staining was observed in a subset of all of these cases ( Table 2 ). Only in one of these cases a rhabdomyosarcoma showed focal Sox10 positivity, and none showed strong and diffuse Sox10 staining (Fig. 2 ). Sox10 and S100 were both reliably expressed at the protein level in schwannomas (45/50, 90%), and neurofibromas (52/55, 95%). Of the 5 Sox10-negative schwannomas, 2 of these cases also showed no evidence of S100 expression (Fig. 3 ). Sox10 and S100 dual positivity was also identified in granular cell tumor (n = 26), and ganglioneuroma (n = 2). Excluding MPNSTs, in tumors of neural crest origin, Sox10 was positive in 137 of 148 (sensitivity 93%) cases and S100 was positive in 140 of 148 cases (sensitivity 95%).
Both Sox10 and S100 showed highly variable protein expression in MPNSTs. Of 78 cases, 44 cases (56%) showed no evidence of either Sox10 or S100 expression. Eighteen cases were dual positive. Thirteen cases (17%) showed S100 expression without Sox10 expression, and 3 cases (4%) were positive for Sox10 and negative for S100 (Fig. 3) . The sensitivity of Sox10 and S100 for the detection of MPNST was 27% and 40%, respectively.
We examined a total of 668 cases of mesenchymal neoplasms of nonschwannian, nonmelanocytic soft tissue origin with Sox10 and S100. The results are summarized in Table 3 . These cases include the aforementioned sarcomas. Sox10 staining was seen in 5 cases (99% specificity). S100 was positive in 53 of 668 cases (91% specificity). Dual Sox10 and S100 staining was seen in cases diagnosed as malignant fibrous histiocytoma (focal) and sarcoma not otherwise specified (strong and diffuse). These cases may represent unrecognized MPNSTs. A single case of nodular faciitis showed focal Sox10 staining and strong and diffuse staining for S100. A single case of digital fibroma showed focal Sox10 staining (no tissue was available for S100 staining). Five glomus tumors were stained. Three of these cases showed S100 positivity, 2 strong and diffuse, and 1 with focal staining. Sox10 was also focally positive in the latter case.
Four cases of perineurioma were evaluated. None showed Sox10 expression.
We identified a subset of sarcomas in which Sox10 stained a greater number of the tumor cell nuclei. These tumors included clear-cell sarcoma (4/7 cases) and desmoplastic melanoma (7/9 cases).
We stained 33 normal tissue types for Sox10. Sox10-negative normal tissues included adrenal, appendix, bladder, cervix, colon, duodenum, endometrium, epididymis, esophagus, gallbladder, heart, kidney, liver, lung, ovary, pancreas, parathyroid, placenta, prostate, seminal vesicle, skeletal muscle, skin, small bowel, spleen, stomach, testis, thyroid, tonsil, umbilical cord, and uterus. A number of normal tissues were Sox10 positive. These included the Schwann cells of peripheral nerve, as well as myoepithelial cell population of the breast and acinar and myoepithelial cells of salivary gland tissue (salivary gland duct epithelium was Sox10 negative). As has been reported in prior studies, mast cells stained positively for Sox10. The staining pattern was predominantly cytoplasmic, but nuclear staining was also seen. 14 
DISCUSSION
Nonaka et al 14 have characterized Sox10 as a sensitive and specific marker for schwannian and melanocytic tumors. We confirmed this conclusion on a larger experimental data set, both in terms of numbers of specimens and pathologies evaluated. They reported no evidence of Sox10 expression in synovial sarcoma, rhabdomyosarcoma, and chondrosarcoma. Our results support this assessment: synovial sarcoma (0/79), rhabdomyosarcoma (0/17), and chondrosarcoma (0/4). We also observed a strong S100 protein expression in cases where no Sox10 protein expression was identified other than non-neural, nonmelanocytic sarcoma types: Ewing sarcoma (3/14) and extraskeletal myxoid chondrosarcoma (5/11). The use of Sox10 in the place of S100 when faced with a spindle cell tumor of uncertain differentiation may prevent misdiagnosis as MPNSTs. The MPNSTs evaluated in this series were diagnosed using strict criteria and either arose in patients with NF1, or were clearly derived from a major nerve with compatible histology. 17 We think that the absence of Sox10 expression is of particular clinical use in cases of cellular schwannoma, as this tumor can demonstrate morphologic similarities to fibrosarcoma, leiyomyosarcoma, and synovial sarcoma, particularly in cases with monophasic histology, or in needle biopsy specimens. Synovial sarcoma in particular has reported to express S100 in up to 30% of cases. 19 Distinguishing between these entities on the basis of morphology can be particularly challenging on small needle biopsy specimens. If presented with a cellularspindled S100-positive neoplasm, fluorescence in situ hybridization to evaluate for t(X;18) or immunohistochemical staining with TLE1 may be necessary to exclude synovial sarcoma. 17, 20 In our study, we examined 79 cases of synovial sarcoma (65 cases on TMA). Of the 12 S100-positive cases (15%), 4 of these cases featured strong, diffuse staining. None of these cases showed Sox10 positivity. In addition, no significant SOX10 gene expression was identified in 40 cases of synovial sarcoma. Given the gene and protein expression results described in this study, if a tumor shows strong Sox10 protein FIGURE 2. S100-positive/Sox10-negative sarcomas. A, Synovial sarcoma, S100 ( Â 200); (B) synovial sarcoma Sox10 ( Â200); (C) rhabdomyosarcoma, S100 ( Â200); (D) rhabdomyosarcoma Sox10 (Â 200); (E) Ewing sarcoma, S100 ( Â200); (F) Ewing sarcoma, Sox10 (Â 200); (G) chondrosarcoma, S100 ( Â200); (H) Chondrosarcoma, Sox10 ( Â200); (I) extraskeletal myxoid chondrosarcoma, S100 ( Â200); (J) extraskeletal myxoid chondrosarcoma, Sox10 ( Â 200).
expression, a diagnosis of synovial sarcoma is unlikely. Negative Sox10 staining in combination with TLE1 expression would conversely provide strong support for a diagnosis of synovial sarcoma. 17, 20 Sox10 was reliably positive in both neurofibromas and schwannomas, in both cases staining the schwannian cell population. Unique to Sox10 is its exclusive nuclear localization in Schwann cells, which typically also demonstrate cytoplasmic S100 staining. Both nuclear and cytoplasmic S100 positivity is present in Schwann cells and melanocytes, and consequently the lack of nuclear positivity is a potential diagnostic pitfall. 21 Granular cell tumors are typically benign tumors of the peripheral nerve characterized by monotonous ovoid to polyhedral cells with distinct cell borders and abundant eosinophillic granular cytoplasm. Sox10 showed strong and diffuse nuclear positivity in all 26 cases of granular cell tumor (Fig. 4) . The granular cell tumors in this study arose in a number of sites including skin, soft tissue, and the aerodigestive tract (larynx and esophagus). Evidence of the Schwann cell derivation of granular cell tumor was in part based on S100 immunoreactivity, 22 and our results provide further support that granular cell tumors are of neural crest derivation. 23 All 4 cases of perineurioma in this series showed no evidence of Sox10 expression. This is consistent with the current understanding that perineurium is derived from transformed mesenchymal tissue as opposed to neural crest. 24 These results are also in-keeping with the traditionally S100-negative immunophenotype of perineurial tumors. 19 Variable staining for S100 in MPNSTs is well described in the literature. 23, 25, 26 Our evaluation of S100 gene expression in MPNST correlates with inconsistent staining for S100 by immunohistochemistry. Sox10 gene expression was similarly variable, though correlated with S100 expression. In our series Sox10 was a less sensitive marker than S100 in cases of MPNST. Though the majority of cases of MPNST were negative for both markers (44/78, 56%), S100 was positive in 13 cases that were Sox10 negative, whereas Sox10 was positive in 3 cases that were negative for S100. Given the 16 cases of MPNST that were positive for only one of these markers, we suggest that a combination of these markers should be used when considering a diagnosis of MPNST in the setting of an undifferentiated tumor.
Sox10 has previously been shown to be superior to S100 in the identification of desmoplastic melanoma. 27 Our study confirmed these findings, and Sox10 showed stronger expression than S100 in 7 of 9 unique cases. In addition, Sox10 showed stronger staining than S100 in 4 of 7 cases of clear-cell sarcoma. As is the case with S100, Sox10 positivity does not distinguish MPNST from melanoma.
We did observe that Sox10 is not exclusively expressed in neural crest tissue, and that it stained the myoepthelial cells of breast tissue and myoepithelial and acinar cells of salivary gland tissue and as such is not a purely specific marker of neural crest derivation. Nonetheless we think that in the realm of soft-tissue neoplasms that Sox10 is significantly more specific than S100 for peripheral nerve sheath tumors and should be used in the place of or along side S100 for diagnostic purposes. 
